Denosumab NEW
Price | $178 | $537 | $775 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-15 |
Product Details
Product Name: Denosumab | CAS No.: 615258-40-7 |
Purity: 99.90% | Supply Ability: 10g |
Release date: 2024/11/15 |
Product Introduction
Bioactivity
名稱 | Denosumab |
描述 | Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand |
存儲條件 | store at low temperature | store at -20°C | Shipping with blue ice. |
關鍵字 | Ranmark | RANKL | Osteoporosis | Nuclear factor-κB | Nuclear factor-kappaB | NF-κB | Inhibitor | inhibit | Immunoglobulin G-2 | Immunoglobulin G2 | Immunoglobulin G 2 | Denosumab | Cancer |
相關產品 | Boldine | Narlumosbart | NFATc1-IN-1 | Alisol B |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/25kg |
Shaanxi Haibo Biotechnology Co., Ltd
|
2023-09-04 | ||
$0.00/1mg |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2023-02-09 | |
$0.00/10mg |
Hangzhou Huarong Pharm Co., Ltd.
|
2021-09-15 | ||
$1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-07-02 | |
$0.00/1Kg |
VIP5Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-04-30 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY